Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to ocular toxoplasmosis.

Pandey N, Dwivedi V.

Indian J Ophthalmol. 2013 Feb;61(2):86. doi: 10.4103/0301-4738.107211. No abstract available.

2.

Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to ocular toxoplasmosis.

Shah NJ, Shah UN.

Indian J Ophthalmol. 2011 Jul-Aug;59(4):318-9. doi: 10.4103/0301-4738.82005.

3.
4.

Intravitreal bevacizumab for choroidal neovascularization in toxoplasmosis.

Guthoff R, Goebel W.

Acta Ophthalmol. 2009 Sep;87(6):688-90. doi: 10.1111/j.1755-3768.2008.01319.x. Epub 2008 Jul 8. No abstract available.

5.

Positive response to intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to punctate inner choroidopathy.

Menezo V, Cuthbertson F, Downes SM.

Retina. 2010 Oct;30(9):1400-4. doi: 10.1097/IAE.0b013e3181d374dc.

PMID:
20224465
6.

Intravitreal bevacizumab for choroidal neovascularization secondary to inflammation.

Wolf A, Thurau S, Kook D, Hoeing A, Priglinger S, Kampik A, Haritoglou C.

Acta Ophthalmol. 2010 Nov;88(7):e295-6. doi: 10.1111/j.1755-3768.2009.01681.x. No abstract available.

7.

Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial.

Heier JS, Brown D, Ciulla T, Abraham P, Bankert JM, Chong S, Daniel PE Jr, Kim IK.

Ophthalmology. 2011 Jan;118(1):111-8. doi: 10.1016/j.ophtha.2010.04.016. Epub 2010 Aug 3.

PMID:
20678799
8.

Intravitreal ranibizumab for choroidal neovascularization secondary to acute multifocal posterior placoid pigment epitheliopathy.

Mavrakanas N, Mendrinos E, Tabatabay C, Pournaras CJ.

Acta Ophthalmol. 2010 Mar;88(2):e54-5. doi: 10.1111/j.1755-3768.2009.01541.x. Epub 2009 Jun 1. No abstract available.

9.

Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to traumatic choroidal rupture.

Chanana B, Azad RV, Kumar N.

Eye (Lond). 2009 Nov;23(11):2125-6. doi: 10.1038/eye.2008.434. Epub 2009 Jan 23. No abstract available.

PMID:
19169235
10.

Intravitreal ranibizumab as primary treatment for neovascular membrane associated with angioid streaks.

Lazaros K, Leonidas Z.

Acta Ophthalmol. 2010 May;88(3):e100-1. doi: 10.1111/j.1755-3768.2009.01754.x. Epub 2009 Nov 7. No abstract available.

11.

Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.

Lai TY, Chan WM, Liu DT, Lam DS.

Retina. 2009 Jun;29(6):750-6. doi: 10.1097/IAE.0b013e31819ed6bd.

PMID:
19357555
12.

Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to endogenous endophthalmitis.

Sheu SJ.

Kaohsiung J Med Sci. 2009 Nov;25(11):617-21. doi: 10.1016/S1607-551X(09)70566-2.

13.

Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia.

Lalloum F, Souied EH, Bastuji-Garin S, Puche N, Querques G, Glacet-Bernard A, Coscas G, Soubrane G, Leveziel N.

Retina. 2010 Mar;30(3):399-406. doi: 10.1097/IAE.0b013e3181bcef24.

PMID:
20038864
14.
15.

Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results.

Silva RM, Ruiz-Moreno JM, Rosa P, Carneiro A, Nascimento J, Rito LF, Cachulo ML, Carvalheira F, Murta JN.

Retina. 2010 Mar;30(3):407-12. doi: 10.1097/IAE.0b013e3181c9691e.

PMID:
20094007
16.

Intravitreal bevacizumab for subfoveal choroidal neovascularization complicating active central serous chorioretinopathy.

Mandal S, Sinha S, Abbas Z, Venkatesh P.

Indian J Ophthalmol. 2011 Jul-Aug;59(4):338-9. doi: 10.4103/0301-4738.82021. No abstract available.

17.

Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results.

Monés JM, Amselem L, Serrano A, Garcia M, Hijano M.

Eye (Lond). 2009 Jun;23(6):1275-80; quiz 1281. doi: 10.1038/eye.2009.88. Epub 2009 May 29.

PMID:
19478826
18.

Intravitreal Ranibizumab in the treatment of choroidal neovascularisation secondary to ocular toxocariasis in a 13-year-old boy.

Lyall DA, Hutchison BM, Gaskell A, Varikkara M.

Eye (Lond). 2010 Nov;24(11):1730-1. doi: 10.1038/eye.2010.131. Epub 2010 Oct 8. No abstract available.

PMID:
20930857
19.

Intravitreal bevacizumab for parapapillary choroidal neovascularization due to exudative age-related macular degeneration.

Jonas JB, Tao Y, Rensch F.

Acta Ophthalmol. 2011 Feb;89(1):e105-7. doi: 10.1111/j.1755-3768.2009.01820.x. No abstract available.

20.

Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab.

Barbazetto I, Saroj N, Shapiro H, Wong P, Freund KB.

Retina. 2010 Oct;30(9):1376-85. doi: 10.1097/IAE.0b013e3181dcfb0b.

PMID:
20683380

Supplemental Content

Support Center